Serious cardiovascular events were rare MS patients receiving high-efficacy disease modifying treatments
MS patients have a generally increased risk of cardiovascular disease, but there is little data on how different disease modifying treatments may alter this risk in patients treated in clinical practice. In this MEDtalk Thomas Frisell will give you an answer.
Sporadic cases of fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. In this MEDtalk Trygve Holmøy present a study based on European Medicines Agency database of suspected adverse reactions related to medicinal products in the European Economic Area (EudraVigilance), for fatal adverse events associated with treatment with alemtuzumab. Trygve Holmøy and colleagues identified nine cases with a probable and one case with a possible causal relationship between alemtuzumab treatment and a fatal adverse event.